{"id":3226,"date":"2018-09-20T16:23:16","date_gmt":"2018-09-20T10:53:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3226"},"modified":"2021-07-24T12:57:04","modified_gmt":"2021-07-24T07:27:04","slug":"the-business-cocktail-40","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-40","title":{"rendered":"Epic Sciences garners; Tvardi gets financing; Galera raises; Fund for cancer research"},"content":{"rendered":"

Epic Sciences garners USD 52 Million for blood tests in cancer patients <\/strong><\/p>\n

Epic Sciences<\/strong> received USD 52 million<\/strong> to progress its suite of liquid biopsies that utilizes computer vision and machine learning to find circulating tumour cells while characterizing the immune response of the body at the same time. The Cancer blood test company also ruminates to utilize the new funds to club its tests with electronic health records and big data analytics to begin patterns in cancer<\/a> cell evolution, drug selection and clinical outcomes.<\/p>\n

\n

Tvardi Therapeutics gets financing for STAT3-driven diseases candidate TTI-101 program<\/strong><\/p>\n

Tvardi Therapeutics<\/strong> has apprised regarding the completion of a USD 9 million <\/strong>Series A financing round. The funding will facilitate the completion of ongoing Phase I studies<\/strong> for lead compound TTI-101<\/strong> of Tvardi in solid tumor cancers. The STAT3<\/strong>-driven diseases have noteworthy societal and economic impact and the positive development of a safe and effective STAT3 inhibitor<\/strong> such as TTI-101 <\/strong>could transform the lives of millions of patients affected with the diseases.<\/p>\n

\n

Galera Therapeutics<\/strong> raises USD 150 Million for testing radiation side effect drug in phase 3<\/strong><\/p>\n

Galera Therapeutics<\/strong> has\u00a0reeled in\u00a0USD 150 million<\/strong> that will bring a drug designed to prevent inflammatory side effects from radiation therapy into a pivotal phase 3 study. The financing comes when GC4419<\/strong> showed to ward off severe oral mucositis<\/strong> (SOM) in patients with head and neck cancers<\/a>. Some of new investors like Nan Fung Life Sciences and RA Capital taken a part, while existing sponsors like New Enterprise Associates, Novartis Venture Fund, Novo Ventures and Sofinnova Ventures also joined.<\/p>\n

\n

The 3 main international charities fund USD 39.4 million<\/strong> after Brexit in cancer research model<\/strong><\/p>\n

Three chief international cancer charities contemplate to invest about USD 39.4 million<\/strong> in six U.K. and European research projects, so to provide a collaboration model. The partnership between Cancer Research UK, the Italian Association for Cancer Research and the Spanish Association Against Cancer<\/strong> is intended to speed up translational research at academic centres in immunotherapies, CAR-T cell production, drug resistance, diagnostics and more.<\/p>\n

\n

\n

\n","protected":false},"excerpt":{"rendered":"

Epic Sciences garners USD 52 Million for blood tests in cancer patients Epic Sciences received USD 52 million to progress its suite of liquid biopsies that utilizes computer vision and machine learning to find circulating tumour cells while characterizing the immune response of the body at the same time. The Cancer blood test company also […]<\/p>\n","protected":false},"author":1,"featured_media":3157,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1842,1851,1847,1848,1846,1844,1845,1583,1849,1852,1843,1841,1850],"industry":[17225],"therapeutic_areas":[17235,17228,17278],"class_list":["post-3226","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cancer-research-uk","tag-epic-sciences","tag-new-enterprise-associates","tag-novartis-venture-fund","tag-novo-ventures","tag-severe-oral-mucositis-som","tag-sofinnova-ventures","tag-stat3","tag-stat3-inhibitor","tag-the-cancer-blood-test-company","tag-the-italian-association-for-cancer-research","tag-the-spanish-association-against-cancer","tag-tvardi-therapeutics","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"\nEpic Sciences garners; Tvardi gets financing; Galera raises<\/title>\n<meta name=\"description\" content=\"Epic Sciences received USD 52 million to progress its suite of liquid biopsies that utilizes computer vision and machine learning to find circulating tumour\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-40\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Epic Sciences garners; Tvardi gets financing; Galera raises\" \/>\n<meta property=\"og:description\" content=\"Epic Sciences received USD 52 million to progress its suite of liquid biopsies that utilizes computer vision and machine learning to find circulating tumour\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-40\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-20T10:53:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Epic Sciences garners; Tvardi gets financing; Galera raises","description":"Epic Sciences received USD 52 million to progress its suite of liquid biopsies that utilizes computer vision and machine learning to find circulating tumour","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-40","og_locale":"en_US","og_type":"article","og_title":"Epic Sciences garners; Tvardi gets financing; Galera raises","og_description":"Epic Sciences received USD 52 million to progress its suite of liquid biopsies that utilizes computer vision and machine learning to find circulating tumour","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-40","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-09-20T10:53:16+00:00","article_modified_time":"2021-07-24T07:27:04+00:00","og_image":[{"width":620,"height":410,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-40","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-40","name":"Epic Sciences garners; Tvardi gets financing; Galera raises","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-40#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-40#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","datePublished":"2018-09-20T10:53:16+00:00","dateModified":"2021-07-24T07:27:04+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Epic Sciences received USD 52 million to progress its suite of liquid biopsies that utilizes computer vision and machine learning to find circulating tumour","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-40"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-40#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","width":620,"height":410,"caption":"Johnson & Johnson"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1-300x198.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer Research UK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Epic Sciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">New Enterprise Associates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis Venture Fund<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novo Ventures<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">severe oral mucositis (SOM)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sofinnova Ventures<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">STAT3<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">STAT3 inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">The Cancer blood test company<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">the Italian Association for Cancer Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">the Spanish Association Against Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tvardi Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer Research UK<\/span>","<span class=\"advgb-post-tax-term\">Epic Sciences<\/span>","<span class=\"advgb-post-tax-term\">New Enterprise Associates<\/span>","<span class=\"advgb-post-tax-term\">Novartis Venture Fund<\/span>","<span class=\"advgb-post-tax-term\">Novo Ventures<\/span>","<span class=\"advgb-post-tax-term\">severe oral mucositis (SOM)<\/span>","<span class=\"advgb-post-tax-term\">Sofinnova Ventures<\/span>","<span class=\"advgb-post-tax-term\">STAT3<\/span>","<span class=\"advgb-post-tax-term\">STAT3 inhibitor<\/span>","<span class=\"advgb-post-tax-term\">The Cancer blood test company<\/span>","<span class=\"advgb-post-tax-term\">the Italian Association for Cancer Research<\/span>","<span class=\"advgb-post-tax-term\">the Spanish Association Against Cancer<\/span>","<span class=\"advgb-post-tax-term\">Tvardi Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 20, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 20, 2018 4:23 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3226"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3226\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3157"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3226"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3226"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}